Lates News

On the morning of June 23rd, Sihuan Pharmaceutical Group announced on the Hong Kong Stock Exchange that the group's developed Meloxicam Injection () has obtained the drug registration approval letter issued by the China National Medical Products Administration. The approved indication for this approval is "for the treatment of moderate to severe pain in adults." This is the first intravenous nanocrystal product approved in China.